Full Text View
Tabular View
No Study Results Posted
Related Studies
Insulin-like Growth Factor-1 (IGF-1) in Amyotrophic Lateral Sclerosis (ALS) Trial
This study has been completed.
First Received: May 6, 2002   Last Updated: July 30, 2009   History of Changes
Sponsor: Mayo Clinic
Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by: Mayo Clinic
ClinicalTrials.gov Identifier: NCT00035815
  Purpose

The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: insulin-like growth factor-1 (IGF-I)
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control
Official Title: Insulin-like Growth Factor-1 (IGF-1) in Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Estimated Enrollment: 330
Study Completion Date: December 2007
Detailed Description:

The objective of this trial is to determine whether IGF-1 (MyotrophinTM) slows progression of weakness in amyotrophic lateral sclerosis (ALS). Three hundred patients with ALS from 16 medical centers will participate in this double blind, placebo-controlled two-year study. Half the patients will receive IGF-1 and the other half will receive placebo. The drug will be administered twice a day.

ALS is a neurodegenerative disorder that causes progressive muscle weakness and loss of motor neurons. IGF-1 is a neurotrophic factor essential for normal development of the nervous system and shows protection of motor neurons in animal models and cell culture systems. It is thought to block cell death pathways and promote muscle re-innervation and axonal growth and regeneration.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients entering this study:

  • Are between the ages of 18-80 years old.
  • Legal residents of the United States or Canada.
  • Have a history of a chronic onset of a progressive motor weakness of less than 24 months duration.
  • Fulfill El Escorial criteria of probable or definite ALS.
  • If female, are surgically sterile, two years postmenopausal, or if of child-bearing potential, must be using a medically acceptable method of birth control and agree to continue use of this method for the duration of the study. Acceptable methods include a barrier method with spermicide, oral contraceptives (normal doses are acceptable; low dose oral contraceptives or contraceptive implants must be used with a barrier method), IUD, or abstinence. Have a negative pregnancy test.
  • Are able to comply with protocol requirements.
  • Can provide written informed consent.
  • Have a manual muscle testing score of less than 8.
  • Have a forced vital capacity by pulmonary function testing *60% predicted.

Exclusion Criteria:

Patients entering this study will not:

  • Have any of the following conditions:renal disease (Creatine > 2.0) or other active systemic disease
  • Have any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam.
  • Have any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient.
  • Have Type I or Type II diabetes.
  • Have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline) and carcinoma in-situ of the cervix (women only).
  • Have used an investigational drug within 30 days of baseline visit.
  • Have had a tracheostomy.
  • Have a Beck's Depression Inventory score * 12.
  • Have legal residency outside of the United States or Canada.
  • Be pregnant or breast-feeding.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00035815

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Eric Sorenson, M.D. Department of Neurology, Mayo Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: Mayo Clinic ( Eric Sorenson, M.D., Department of Neurology )
Study ID Numbers: 1461-01, R01NS42759
Study First Received: May 6, 2002
Last Updated: July 30, 2009
ClinicalTrials.gov Identifier: NCT00035815     History of Changes
Health Authority: United States: Federal Government

Keywords provided by Mayo Clinic:
amyotrophic lateral sclerosis
ALS
progressive weakness
insulin-like growth factor-1
IGF-I
Myotrophin

Additional relevant MeSH terms:
Spinal Cord Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Nervous System Diseases
Mitosis Modulators
Central Nervous System Diseases
Sclerosis
Neurodegenerative Diseases
Pharmacologic Actions
Insulin
Hypoglycemic Agents
Pathologic Processes
Neuromuscular Diseases
Amyotrophic Lateral Sclerosis
Mitogens
Motor Neuron Disease

ClinicalTrials.gov processed this record on November 27, 2009